Selected article for: "Cox regression and survival rate"
Author: Scarsi, Mirko; Piantoni, Silvia; Colombo, Enrico; Airó, Paolo; Richini, Donata; Miclini, Marco; Bertasi, Valeria; Bianchi, Marta; Bottone, Damiano; Civelli, Patrizia; Cotelli, Maria-Sofia; Damiolini, Ezio; Galbassini, Gloria; Gatta, Diego; Ghirardelli, Maria-Laura; Magri, Roberto; Malamani, Paola; Mendeni, Monia; Molinari, Stefano; Morotti, Andrea; Salada, Luisa; Turla, Marinella; Vender, Angiola; Tincani, Angela; Brucato, Antonio; Franceschini, Franco; Furloni, Roberto; Andreoli, Laura
Title: Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
  • Cord-id: 8dobncuw
  • Document date: 2020_7_30
    • ID: 8dobncuw
    Snippet: OBJECTIVES: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with ‘standard-of-care’ (SoC). METHODS: In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed CO
    Document: OBJECTIVES: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with ‘standard-of-care’ (SoC). METHODS: In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5–19 March 2020, were treated with ‘SoC’ (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction). RESULTS: Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%) vs 63.6% (SE=4.1%), p=0.001). Cox proportional hazards regression survival analysis showed that a lower risk of death was independently associated with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), p<0.0001), whereas older age, worse PaO2/FiO2, and higher serum levels of ferritin at entry were associated with a higher risk. CONCLUSION: This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • acute ards respiratory distress syndrome and admission day mortality: 1, 2
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • acute ards respiratory distress syndrome and lopinavir ritonavir antiviral treatment: 1, 2
    • acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acute ards respiratory distress syndrome and lymphohistiocytosis syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome pneumonia and admission day: 1, 2, 3, 4
    • acute ards respiratory distress syndrome pneumonia and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome pneumonia and lung damage: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome pneumonia and lymphohistiocytosis syndrome: 1, 2
    • adjunct treatment and admission day: 1, 2, 3
    • adjunct treatment and admission day mortality: 1
    • adjunct treatment and lung damage: 1
    • administration timing dosage and lopinavir ritonavir: 1
    • admission day and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • admission day and lung damage: 1, 2, 3, 4
    • admission day mortality and lopinavir ritonavir: 1, 2, 3
    • admission day mortality and lung damage: 1